Targeted cancer therapy: What if the driver is just a messenger? Journal Article


Authors: Schatz, J. H.; Wendel, H. G.
Article Title: Targeted cancer therapy: What if the driver is just a messenger?
Abstract: "Shoot the driver" is the paradigm of targeted cancer therapy. However, resistance to targeted inhibitors of signaling pathways is a major problem. In part the redundancy of signaling networks can bypass targeted inhibitors and thereby reduce their biological effect. In this case the driver turns out to be one of several potential messengers and is easily replaced. Cocktails of multiple targeted inhibitors are an obvious solution. This is limited, however, by the lack of potent inhibitors and may also produce increased toxicity. Therefore we explored the direct blockade of a key biological activity downstream from multiple converging oncogenic signals. Specifically, several oncogenic signaling pathways including AKT, MAPK and PIM kinase signals converge on the activation of cap-dependent translation. In cancer cells, aberrant activation of cap-dependent translation favors the increased expression of short-lived oncoproteins like c-MYC, MCL1, CYCLIN D1 and the PIM kinases. Intriguingly, cancer cells are especially sensitive to even temporary reductions in these proteins. We will discuss our findings concerning translational inhibitor therapy in cancer.
Keywords: survival; lymphoma; translation; targeted therapy; akt; cap; growth; rearrangements; mechanisms; eif4e; oncogenesis; sequencing reveals
Journal Title: Cell Cycle
Volume: 10
Issue: 22
ISSN: 1538-4101
Publisher: Taylor & Francis Inc.  
Date Published: 2011-11-01
Start Page: 3830
End Page: 3833
Language: English
ACCESSION: WOS:000297168600018
DOI: 10.4161/cc.10.22.18288
PROVIDER: wos
PUBMED: 22064518
PMCID: PMC3266113
Notes: --- - Article - "Source: Wos"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Hans Guido Wendel
    102 Wendel
  2. Jonathan Harry Schatz
    15 Schatz